Although Omicron subvariants of the SARS-CoV-2 pandemic coronavirus have evolved to evade antibody responses from the primary COVID-19 vaccine series, a new laboratory study suggests current vaccine boosters may elicit sufficient immune protection against severe Omicron-induced COVID-19 disease. The project assessed a comprehensive panel of vaccines available in the United States and around the world, as well as immunity acquired through previous infection. The international research team was led by the lab of David Veesler, associate professor of biochemistry at the University of Washington School of Medicine in Seattle and an investigator at the Howard Hughes Medical Institute. “The development of lifesaving vaccines is regarded as one of humanity’s greatest medical and scientific achievements, which is exemplified by COVID-19 vaccines,” the project team noted. The protective immunity generated by the primary vaccine series or prior infection has been severely blunted by Omicron subvariants. A booster dose, regardless of the type of COVID-19...
🔒 Premium Content - For Free
Unlock this content by becoming a Global Health Press subscriber. Join for exclusive articles, expert research, and valuable insights!




